Glucagon Test

Your fasting blood sugar can look perfectly normal while the hormonal machinery behind it is already breaking down. Glucagon is the hormone that keeps your blood sugar from dropping too low, and when its levels are persistently elevated, it often signals that your liver is struggling to respond to it properly. That disconnect between a normal glucose reading and a rising glucagon level is one of the earliest metabolic warning signs you can catch.

Glucagon (produced by alpha cells in the pancreas) works as the mirror image of insulin. While insulin lowers blood sugar after meals, glucagon raises it between meals by telling the liver to release stored glucose. These two hormones should operate in a tightly coordinated balance. When that balance breaks, glucagon is often the first number to shift, sometimes years before glucose or HbA1c move out of range.

How Glucagon Works

When you haven't eaten for several hours, your blood sugar starts to dip. Your pancreatic alpha cells sense this drop and release glucagon into the bloodstream. Glucagon travels to the liver, where it triggers two processes: breaking down stored glycogen (a starch-like reserve) into glucose, and manufacturing new glucose from amino acids and other building blocks. The result is a steady supply of fuel to your brain and muscles between meals.

Beyond its classic role in blood sugar regulation, glucagon plays a less appreciated but equally important role in protein metabolism. When you eat protein, the amino acids in your meal stimulate glucagon release. Glucagon then tells the liver to process those amino acids, converting the nitrogen they contain into urea for safe elimination through the kidneys. This loop between amino acids and glucagon is called the liver-alpha cell axis, and it turns out to be central to understanding why glucagon goes wrong in metabolic disease.

Fatty Liver and Glucagon Resistance

One of the most important recent discoveries about glucagon is its tight connection to fatty liver disease. When fat accumulates in the liver (a condition now called metabolic dysfunction-associated steatotic liver disease, or MASLD), the liver becomes resistant to glucagon's instructions to process amino acids. Amino acids then build up in the blood, and those elevated amino acids stimulate the pancreas to produce even more glucagon, creating a self-reinforcing cycle.

A study of individuals with liver steatosis (fatty liver confirmed by imaging) found that elevated glucagon correlated with hepatic fat itself, independent of body weight, BMI, or type 2 diabetes status. This means glucagon can flag liver fat in someone who is not overweight and has normal blood sugar. Fasting glucagon levels also correlated strongly with liver fat content during a very low-calorie diet study in 10 people with obesity and type 2 diabetes (correlation coefficient 0.52), and both glucagon and liver fat dropped by nearly 30% together over seven weeks.

Type 2 Diabetes Risk

Elevated glucagon is not just a marker of existing metabolic problems. It predicts future diabetes. In the UK Biobank study of approximately 40,000 participants followed for 14 years, higher levels of proglucagon (the precursor protein from which glucagon is made) predicted new-onset type 2 diabetes with a hazard ratio of 1.13 per unit increase. That association held across all BMI categories, meaning it was not simply a proxy for being overweight.

A meta-analysis of oral glucose tolerance test studies found that people with prediabetes already show inadequate glucagon suppression after drinking a glucose solution. In healthy individuals, glucagon drops sharply after a sugar load because the body no longer needs the liver to produce glucose. In prediabetes, glucagon stays elevated, forcing the pancreas to produce extra insulin to compensate. Fasting glucagon levels in people with prediabetes averaged about 34.4 pg/mL compared to 20.6 pg/mL in those with normal glucose tolerance.

In a smaller prospective study (the Hoorn Meal Study), 121 people without diabetes were followed for seven years. Those with a stronger early glucagon response to a mixed meal test saw their fasting glucose rise by an additional 0.18 mmol/L over that period compared to those with a lower response.

Heart Disease

Emerging evidence links elevated glucagon to cardiovascular risk, though the data is still maturing. A Mendelian randomization study (which uses genetic variants to estimate causal effects) found that genetically predicted higher glucagon was associated with a modest increase in ischemic heart disease risk (odds ratio 1.03). This approach reduces confounding from shared metabolic risk factors.

In a cross-sectional study of 1,739 hospitalized patients with type 2 diabetes, each standard-deviation increase in fasting glucagon was associated with about 1.5 times higher odds of coronary artery disease in women (odds ratio 1.49). This sex-specific finding needs confirmation in larger prospective studies, but it raises the possibility that glucagon adds cardiovascular risk information beyond standard glucose and lipid testing, at least in certain populations.

Kidney Disease

Your kidneys are the primary site where glucagon is cleared from the bloodstream. In chronic kidney disease (CKD), glucagon clearance drops by roughly 58%, which means blood levels rise even without any increase in secretion. A study of 357 people with type 2 diabetes found that glucagon levels were significantly higher in those whose kidney filtration rate (eGFR) was below 60 mL/min, and glucagon independently correlated with eGFR.

This creates an interpretive challenge: if your kidney function is reduced, an elevated glucagon level may reflect impaired clearance rather than true overproduction by the pancreas. Knowing your eGFR is essential context for interpreting a glucagon result.

Pediatric and Obesity Connections

Glucagon dysregulation is not limited to adults. A study of over 4,000 children and adolescents (ages 6 to 19) found that those with overweight or obesity had elevated glucagon levels associated with insulin resistance, elevated liver enzyme ALT, abnormal cholesterol, and high blood pressure. Interestingly, higher glucagon was inversely associated with fasting glucose in this young population, suggesting that the hormonal imbalance precedes the glucose abnormalities that eventually define diabetes.

Reference Ranges

Glucagon reference ranges depend heavily on which assay your lab uses. Older radioimmunoassays (RIA) report systematically higher values because they cross-react with fragments of the proglucagon protein that are not actual glucagon. Modern sandwich immunoassays and mass spectrometry methods are more specific and produce lower readings for the same sample. Always compare your results to the reference range provided by the specific lab and assay that processed your blood.

These tiers are drawn from published research and clinical guidelines for glucagonoma diagnosis. Your lab may use different assays and cutpoints. Compare your results within the same lab over time for the most meaningful trend. Fasting glucagon in prediabetes populations has been reported around 34 pg/mL compared to about 21 pg/mL in those with normal glucose tolerance, illustrating that even modest elevations can carry clinical meaning.

Tracking Your Trend

A single glucagon reading is a starting point, not a verdict. The intra-individual coefficient of variation for fasting glucagon is approximately 19%, meaning your level can fluctuate by nearly a fifth from one draw to the next based on normal biological variation alone. To be confident that a change is real rather than random noise, you would need to see a shift of more than 53% between two fasting readings taken under the same conditions.

This variability makes serial tracking essential. Get a baseline fasting glucagon measurement, then retest in three to six months if you are making dietary or lifestyle changes aimed at improving metabolic health or reducing liver fat. After that, annual monitoring lets you see whether your trend is stable, improving, or drifting upward. Pair glucagon with fasting insulin, glucose, and liver enzymes for the most complete picture.

Because different assay methods produce different absolute values, always retest at the same lab. Switching labs can make it look like your glucagon jumped or dropped when the only thing that changed was the measurement technique.

When Results Can Be Misleading

Several factors can distort a glucagon reading and lead you to the wrong conclusion. The most impactful is kidney function: since the kidneys clear glucagon from the blood, even moderate kidney impairment (eGFR below 60) can raise your level by more than 50% without any change in how much glucagon your pancreas is producing. Always interpret glucagon alongside a recent eGFR or creatinine.

Acute illness and physical stress can spike glucagon dramatically. Severe infections have been shown to push glucagon levels to several times normal, and surgery can elevate levels within 24 hours. Acute pancreatitis can cause a ninefold increase. If you had a recent hospitalization, infection, or surgical procedure, wait at least two to three weeks before drawing a fasting glucagon for routine metabolic assessment.

Exercise within 24 hours of testing can also skew results. A meta-analysis found that a single bout of moderate aerobic exercise increases glucagon by about 25 ng/L on average (based on 5 studies in 47 healthy adults). This is a normal physiological response to fuel working muscles, not a sign of metabolic disease. Avoid vigorous exercise the day before your blood draw.

Your most recent meal matters too. Protein-rich meals trigger a large glucagon spike, with high-dose whey protein causing up to an eightfold increase. Even a standard mixed meal elevates glucagon for several hours. Fast for 8 to 12 hours before testing, and keep your pre-test dinner moderate in protein for the cleanest baseline reading. In people with obesity, fasting itself can paradoxically decrease glucagon between 8 and 24 hours (the opposite of what happens in lean individuals), so standardizing fasting duration matters.

• Glucocorticoid medications: Drugs like dexamethasone and prednisone can raise basal glucagon by 55% to 110%. If you take corticosteroids for any reason, your glucagon level may appear elevated without reflecting actual metabolic disease.
• SGLT2 inhibitors: These diabetes medications (dapagliflozin, empagliflozin) raise fasting glucagon by about 8 to 14 pg/mL as a secondary effect of glucose lowering, not because they cause metabolic harm.
• Assay method: Older radioimmunoassays can read two to three times higher than modern sandwich immunoassays for the same sample because they detect non-glucagon peptide fragments. Confirm which assay your lab uses.